Madrigal

Madrigal is a biopharmaceutical company developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Its lead product, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first treatment for MASH to receive approval from the U.S. Food and Drug Administration.

The company's work spans biopharmaceutical drug development and metabolic and liver disease therapeutics, with particular depth in endocrinology and hepatology and THR-β agonist pharmacology. Madrigal describes its mission as restoring balance and harmony to the liver, and concentrates on diseases with significant unmet medical need.

Madrigal began as a small team of researchers and has grown into a fully integrated biopharmaceutical company with hundreds of employees in the United States and Europe. The company traces its origins to Conshohocken, Pennsylvania.